FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc., expanding its labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

SUPPL AP for RYBREVANT (AMIVANTAMAB-VMJW)